Tags

Type your tag names separated by a space and hit enter

Hepatoprotective effects of zingerone on carbon tetrachloride- and dimethylnitrosamine-induced liver injuries in rats.
Arch Pharm Res. 2016 Feb; 39(2):279-291.AP

Abstract

In this study, we investigated the hepatoprotective and anti-fibrotic effects of zingerone, one of the active components of ginger, against carbon tetrachloride (CCl4)- and dimethylnitrosamine (DMN)-induced liver injuries in rats, respectively. Oral administration of zingerone (10 mg/kg) reduced CCl4-induced abnormalities in liver histology, serum alanine aminotransferase and aspartate aminotransferase levels, and liver malondialdehyde levels. Zingerone treatment attenuated CCl4-induced increases in inflammatory mediators, including tumor necrosis factor-α, interleukin-1β, cyclooxygenase-2, and inducible nitric oxide synthase mRNA levels. Western blot analysis showed that zingerone suppressed activation of nuclear factor-kappa B (NF-κB) p65 and phosphorylation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinases (MAPKs). Liver fibrosis induced by DMN (10 mg/kg, intraperitoneally) was ameliorated by administration of zingerone (10 and 20 mg/kg, orally). Zingerone treatment reduced DMN-induced elevation of hydroxyproline content and hepatic stellate cell activation. In conclusion, zingerone showed antioxidative and anti-inflammatory effects in CCl4-intoxicated rats by inhibiting oxidative stress and NF-κB activation via blockade of the activation of upstream MAPKs. Moreover, zingerone had hepatoprotective and anti-fibrotic effects against DMN-induced liver injury suggesting its usefulness in the prevention of liver inflammation and the development of hepatic fibrosis.

Authors+Show Affiliations

College of Pharmacy, Pusan National University, Busan, 46241, Korea.College of Pharmacy, Pusan National University, Busan, 46241, Korea. Hazard Substances Analysis Team, Center for Food and Drug Analysis, Busan Regional Food & Drug Administration, 65, 356-Gil, Shinseon-ro, Nam-gu, Busan, 47366, Korea.College of Pharmacy, Pusan National University, Busan, 46241, Korea.College of Pharmacy, Pusan National University, Busan, 46241, Korea.College of Pharmacy, Pusan National University, Busan, 46241, Korea.College of Pharmacy, Pusan National University, Busan, 46241, Korea.College of Pharmacy, Pusan National University, Busan, 46241, Korea.Department of Anatomy College of Medicine, Pusan National University, Yangsan, 50612, Korea.College of Pharmacy, Pusan National University, Busan, 46241, Korea. mjo@pusan.ac.kr.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26667466

Citation

Cheong, Kyoung Ook, et al. "Hepatoprotective Effects of Zingerone On Carbon Tetrachloride- and Dimethylnitrosamine-induced Liver Injuries in Rats." Archives of Pharmacal Research, vol. 39, no. 2, 2016, pp. 279-291.
Cheong KO, Shin DS, Bak J, et al. Hepatoprotective effects of zingerone on carbon tetrachloride- and dimethylnitrosamine-induced liver injuries in rats. Arch Pharm Res. 2016;39(2):279-291.
Cheong, K. O., Shin, D. S., Bak, J., Lee, C., Kim, K. W., Je, N. K., Chung, H. Y., Yoon, S., & Moon, J. O. (2016). Hepatoprotective effects of zingerone on carbon tetrachloride- and dimethylnitrosamine-induced liver injuries in rats. Archives of Pharmacal Research, 39(2), 279-291. https://doi.org/10.1007/s12272-015-0696-2
Cheong KO, et al. Hepatoprotective Effects of Zingerone On Carbon Tetrachloride- and Dimethylnitrosamine-induced Liver Injuries in Rats. Arch Pharm Res. 2016;39(2):279-291. PubMed PMID: 26667466.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hepatoprotective effects of zingerone on carbon tetrachloride- and dimethylnitrosamine-induced liver injuries in rats. AU - Cheong,Kyoung Ook, AU - Shin,Dong-Su, AU - Bak,Jeonghyeon, AU - Lee,Changyong, AU - Kim,Kyung Wook, AU - Je,Nam Kyung, AU - Chung,Hae Young, AU - Yoon,Sik, AU - Moon,Jeon-Ok, Y1 - 2015/12/14/ PY - 2015/07/13/received PY - 2015/12/08/accepted PY - 2015/12/16/entrez PY - 2015/12/17/pubmed PY - 2016/12/15/medline KW - Anti-fibrotic effect KW - Antioxidant KW - Hepatoprotective effect KW - MAPKs KW - NF-κB KW - Zingerone SP - 279 EP - 291 JF - Archives of pharmacal research JO - Arch Pharm Res VL - 39 IS - 2 N2 - In this study, we investigated the hepatoprotective and anti-fibrotic effects of zingerone, one of the active components of ginger, against carbon tetrachloride (CCl4)- and dimethylnitrosamine (DMN)-induced liver injuries in rats, respectively. Oral administration of zingerone (10 mg/kg) reduced CCl4-induced abnormalities in liver histology, serum alanine aminotransferase and aspartate aminotransferase levels, and liver malondialdehyde levels. Zingerone treatment attenuated CCl4-induced increases in inflammatory mediators, including tumor necrosis factor-α, interleukin-1β, cyclooxygenase-2, and inducible nitric oxide synthase mRNA levels. Western blot analysis showed that zingerone suppressed activation of nuclear factor-kappa B (NF-κB) p65 and phosphorylation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinases (MAPKs). Liver fibrosis induced by DMN (10 mg/kg, intraperitoneally) was ameliorated by administration of zingerone (10 and 20 mg/kg, orally). Zingerone treatment reduced DMN-induced elevation of hydroxyproline content and hepatic stellate cell activation. In conclusion, zingerone showed antioxidative and anti-inflammatory effects in CCl4-intoxicated rats by inhibiting oxidative stress and NF-κB activation via blockade of the activation of upstream MAPKs. Moreover, zingerone had hepatoprotective and anti-fibrotic effects against DMN-induced liver injury suggesting its usefulness in the prevention of liver inflammation and the development of hepatic fibrosis. SN - 0253-6269 UR - https://www.unboundmedicine.com/medline/citation/26667466/Hepatoprotective_effects_of_zingerone_on_carbon_tetrachloride__and_dimethylnitrosamine_induced_liver_injuries_in_rats_ L2 - https://dx.doi.org/10.1007/s12272-015-0696-2 DB - PRIME DP - Unbound Medicine ER -